logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
X

Xia Xu

collegeville
H指数:38
被引数:7,558

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive

BA.1适配型BNT162b2疫苗在18至55岁先前接种过BNT162b2或COVID-19疫苗-naive人群中的免疫原性、耐受性和安全性

Infectious Diseases and Therapy
IF5.3
2026-07-250
OA
David Fitz-Patrick; Omair Sahgal; Leon F. Fouché; Essack Mitha; Mookho Malahleha; Juleen Gayed; Georgina Keep; Ying Zhang; Kayvon Modjarrad; Todd Belanger; Xia Xu; David Cooper; Federico J. Mensa; Uǧur Sahin; Ӧzlem Türeci; Kena A. Swanson; Annaliesa S. Anderson; Alejandra Gurtman; Nicholas Kitchin
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial

单剂量奥密克戎KP.2变异株适应型BNT162b2 COVID-19疫苗在成人中的安全性与免疫原性：一项II/III期临床试验的单臂亚组研究

Infectious Diseases and Therapy
IF5.3
2025-07-010
OAAI
Oyeniyi Diya; Juleen Gayed; Francine S. Lowry; Hua Ma; Vishva Bangad; Federico Mensa; Jing Zou; Xuping Xie; Yanping Hu; Mark Cutler; Todd Belanger; David Cooper; Xia Xu; Robin Mogg; Özlem Türeci; Uǧur Şahin; Kena A. Swanson; Kayvon Modjarrad; Annaliesa S. Anderson; Alejandra Gurtman; Nicholas Kitchin
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old

一项2/3期临床试验，旨在研究单价新冠病毒奥密克戎JN.1变异株适应型BNT162b2疫苗在≥18岁成人中的安全性和免疫原性。

VACCINE
IF3.5
2025-04-010
OAAI
Diya, Oyeniyi; Gayed, Juleen; Lowry, Francine S.; Ma, Hua; Bangad, Vishva; Mensa, Federico; Zou, Jing; Xie, Xuping; Hu, Yanping; Cutler, Mark; Belanger, Todd; Cooper, David; Xu, Xia; Koury, Kenneth; Tuereci, Oezlem; Sahin, Ugur; Swanson, Kena A.; Modjarrad, Kayvon; Anderson, Annaliesa S.; Gurtman, Alejandra; Kitchin, Nicholas
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial

针对XBB.1.5，BA.2.86和JN.1亚系的单价Omicron XBB.1.5适应的BNT162b2新型冠状病毒肺炎疫苗的免疫原性: 2/3期试验

VACCINES
IF3.4
2024-07-024
OAAI
Gayed, Juleen; Bangad, Vishva; Xu, Xia; Mensa, Federico; Cutler, Mark; Tureci, Ozlem; Sahin, Ugur; Modjarrad, Kayvon; Swanson, Kena A.; Anderson, Annaliesa S.; Gurtman, Alejandra; Kitchin, Nicholas
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

单价Omicron XBB.1.5适应的BNT162b2新型冠状病毒肺炎疫苗在 ≥ 12岁个体中的安全性和免疫原性: 2/3期试验

VACCINES
IF3.4
2024-01-2421
OAAI
Gayed, Juleen; Diya, Oyeniyi; Lowry, Francine S.; Xu, Xia; Bangad, Vishva; Mensa, Federico; Zou, Jing; Xie, Xuping; Hu, Yanping; Lu, Claire; Cutler, Mark; Belanger, Todd; Cooper, David; Koury, Kenneth; Anderson, Annaliesa S.; Tureci, Ozlem; Sahin, Ugur; Swanson, Kena A.; Modjarrad, Kayvon; Gurtman, Alejandra; Kitchin, Nicholas
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds

在 ≥ 12岁的儿童中使用二价Omicron-BA.4/BA.5适应的BNT162b2助推器

CLINICAL INFECTIOUS DISEASES
IF7.3
2023-11-288
OAAI
Usdan, Lisa; Patel, Sohil; Rodriguez, Hector; Xu, Xia; Lee, Dung-Yang; Finn, Daniel; Wyper, Hayley; Lowry, Francine S.; Mensa, Federico J.; Lu, Claire; Cooper, David; Koury, Kenneth; Anderson, Annaliesa S.; Tureci, Ozlem; Sahin, Ugur; Swanson, Kena A.; Gruber, William C.; Kitchin, Nicholas

研究方向

暂未获取到该数据
N
Nicholas Kitchin
H 指数:25论文数:70被引数:2.3万
U
Uğur Şahin
H 指数:103论文数:733被引数:6.9万
K
Kena A. Swanson
H 指数:47论文数:146被引数:3.2万
Ö
Özlem Türeci
H 指数:80论文数:422被引数:5.5万
李
李峻柏
H 指数:82论文数:453被引数:2.3万
W
William C. Gruber
H 指数:76论文数:304被引数:4.2万
D
David Cooper
H 指数:45论文数:122被引数:3.1万
黄
黄勇平
H 指数:48论文数:235被引数:8,049
A
Alejandra Gurtman
H 指数:40论文数:140被引数:2.7万
K
Kenneth Koury
H 指数:30论文数:115被引数:3.3万